Travis Snyders1, Daniel Chakos2, Umang Swami3, Emile Latour4, Yiyi Chen4, Maria Fleseriu5, Mohammed Milhem2, Yousef Zakharia2, Roula Zahr5. 1. Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. travis-snyders@uiowa.edu. 2. Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. 3. Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. 4. Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA. 5. Division of Endocrinology, Department of Medicine, Oregon Health and Science University, Portland, OR, USA.
Abstract
BACKGROUND: Immune checkpoint inhibitors, single or in combination, have recently become a cornerstone for the treatment of many malignancies. Ipilimumab, a CTLA-4 inhibitor, was initially FDA approved for treatment of unresectable or metastatic melanoma and subsequently in combination therapy for other cancers. Ipilimumab-induced hypophysitis (IH) risk of development varies in different studies between 0 and 17%. Furthermore, little is known on how to predict which patients will develop IH and its impact on efficacy of Ipilimumab and survival for these patients. Here we reviewed IH and its impact on progression-free survival (PFS) and overall survival (OS). METHODS: Retrospective, IRB- approved review of consecutive 117 melanoma patients who received ipilimumab between 2011 and 2016 was undertaken. Demographic and clinical characteristics, treatment timing and doses, time to progression after therapy, and survival data were reviewed. Patients were predefined in two groups: patients with and without IH. Descriptive statistics were used to summarize the demographic and clinical characteristics of the study sample. All values are shown as means and standard deviation [mean (SD)] unless indicated otherwise. P < 0.05 was considered to be statistically significant. RESULTS: Of the 117 patients, 15 (12.8%) with a median age of 62.1 years developed IH. In the IH cohort, 10 (66.7%) were male and were significantly older than females (median 67.7 vs. 50.8; P = 0.009). This difference was not seen in non-IH group. Male patients with IH were significantly older than males without IH (67.7 vs. 56.4 years, P = 0.020), however this difference was not observed in females. No patient who received prior cancer systemic therapy (0/30) developed IH vs. 17.2% (15/72) without prior therapy developed IH (OR 0.00; 95% CI 0.00 to 0.73, P = 0.011). Between IH and non-IH patients, there was no difference in gender, race, ethnicity, BMI, diabetes or autoimmune disease at baseline, number of administered ipilimumab cycles, presence of primary melanoma lesion, or BRAF status. IH and non-IH patients had a similar median PFS (8.1 vs. 6.8 months, HR = 0.51, 95% CI 0.24 to 1.05 P = 0.062) and OS (53.3 vs. 29.5 months; HR 0.66, 95% CI 0.30 to 1.46; P = 0.307). CONCLUSION: In this study of melanoma patients treated with Ipilimumab, risk of developing IH was high (almost 13%). Older age in men and no prior cancer therapy were associated with IH higher risk. Development of IH was not associated with PFS or OS. Increased use of immune checkpoint inhibitors in the future will impact IH overall risk, thus awareness is needed. Given the lack of reliable identifiable risk factors, close monitoring of signs and symptoms after each therapy cycle is critical for early detection and treatment of hypophysitis.
BACKGROUND: Immune checkpoint inhibitors, single or in combination, have recently become a cornerstone for the treatment of many malignancies. Ipilimumab, a CTLA-4 inhibitor, was initially FDA approved for treatment of unresectable or metastatic melanoma and subsequently in combination therapy for other cancers. Ipilimumab-induced hypophysitis (IH) risk of development varies in different studies between 0 and 17%. Furthermore, little is known on how to predict which patients will develop IH and its impact on efficacy of Ipilimumab and survival for these patients. Here we reviewed IH and its impact on progression-free survival (PFS) and overall survival (OS). METHODS: Retrospective, IRB- approved review of consecutive 117 melanomapatients who received ipilimumab between 2011 and 2016 was undertaken. Demographic and clinical characteristics, treatment timing and doses, time to progression after therapy, and survival data were reviewed. Patients were predefined in two groups: patients with and without IH. Descriptive statistics were used to summarize the demographic and clinical characteristics of the study sample. All values are shown as means and standard deviation [mean (SD)] unless indicated otherwise. P < 0.05 was considered to be statistically significant. RESULTS: Of the 117 patients, 15 (12.8%) with a median age of 62.1 years developed IH. In the IH cohort, 10 (66.7%) were male and were significantly older than females (median 67.7 vs. 50.8; P = 0.009). This difference was not seen in non-IH group. Male patients with IH were significantly older than males without IH (67.7 vs. 56.4 years, P = 0.020), however this difference was not observed in females. No patient who received prior cancer systemic therapy (0/30) developed IH vs. 17.2% (15/72) without prior therapy developed IH (OR 0.00; 95% CI 0.00 to 0.73, P = 0.011). Between IH and non-IH patients, there was no difference in gender, race, ethnicity, BMI, diabetes or autoimmune disease at baseline, number of administered ipilimumab cycles, presence of primary melanoma lesion, or BRAF status. IH and non-IH patients had a similar median PFS (8.1 vs. 6.8 months, HR = 0.51, 95% CI 0.24 to 1.05 P = 0.062) and OS (53.3 vs. 29.5 months; HR 0.66, 95% CI 0.30 to 1.46; P = 0.307). CONCLUSION: In this study of melanomapatients treated with Ipilimumab, risk of developing IH was high (almost 13%). Older age in men and no prior cancer therapy were associated with IH higher risk. Development of IH was not associated with PFS or OS. Increased use of immune checkpoint inhibitors in the future will impact IH overall risk, thus awareness is needed. Given the lack of reliable identifiable risk factors, close monitoring of signs and symptoms after each therapy cycle is critical for early detection and treatment of hypophysitis.
Entities:
Keywords:
Hypophysitis; Immune related adverse side effects; Immunotherapy; Ipilimumab; Malignant melanoma
Authors: Ajay V Maker; James C Yang; Richard M Sherry; Suzanne L Topalian; Udai S Kammula; Richard E Royal; Marybeth Hughes; Michael J Yellin; Leah R Haworth; Catherine Levy; Tamika Allen; Sharon A Mavroukakis; Peter Attia; Steven A Rosenberg Journal: J Immunother Date: 2006 Jul-Aug Impact factor: 4.456
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Le Min; Frank Stephen Hodi; Anita Giobbie-Hurder; Patrick A Ott; Jason J Luke; Hilary Donahue; Meredith Davis; Rona S Carroll; Ursula B Kaiser Journal: Clin Cancer Res Date: 2014-12-23 Impact factor: 12.531
Authors: Patrizio Caturegli; Craig Newschaffer; Alessandro Olivi; Martin G Pomper; Peter C Burger; Noel R Rose Journal: Endocr Rev Date: 2005-01-05 Impact factor: 19.871
Authors: Salvatore Maria Corsello; Agnese Barnabei; Paolo Marchetti; Liana De Vecchis; Roberto Salvatori; Francesco Torino Journal: J Clin Endocrinol Metab Date: 2013-03-07 Impact factor: 5.958
Authors: Alexander T Faje; Ryan Sullivan; Donald Lawrence; Nicholas A Tritos; Riley Fadden; Anne Klibanski; Lisa Nachtigall Journal: J Clin Endocrinol Metab Date: 2014-07-31 Impact factor: 5.958
Authors: M S Siddiqui; Z M Lai; L Spain; V Greener; S Turajlic; J Larkin; D L Morganstein Journal: J Endocrinol Invest Date: 2020-05-24 Impact factor: 4.256